Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3558780 | 0.92 | SCN9A (0.40) | SLC2A1SCN9A | |
| SCHEMBL3556733 | 0.91 | SLC2A1 (0.48) | SLC2A1MMP2MMP9MMP8KCNH2 | |
| SCHEMBL3561339 | 0.89 | SLC2A1 (0.40) | SLC2A1MMP2MMP9MMP8KCNH2 | |
| SCHEMBL4472453 | 0.86 | SLC2A1 (0.58) | SLC2A1MMP2MMP9MMP8KCNH2 | |
| SCHEMBL3711185 | 0.85 | SLC2A1 (0.38) | SLC2A1MMP2MMP9MMP8PTGER4 | |
| SCHEMBL13049774 | 0.85 | DGAT1 (0.40) | KCNH2SCN10A | |
| SCHEMBL3713064 | 0.84 | SLC2A1 (0.38) | SLC2A1MMP2MMP9MMP8PTGER4 | |
| SCHEMBL3718102 | 0.84 | SLC2A1 (0.38) | SLC2A1MMP2MMP9MMP8PTGER4 | |
| SCHEMBL3716508 | 0.84 | SLC2A1 (0.38) | SLC2A1MMP2MMP9MMP8PTGER4 | |
| SCHEMBL13439218 | 0.83 | TLR8 (0.42) | SLC2A1KIF11SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010094738-A1 | PHOSPHATE ESTER OF A 4-PYRIDONE DERIVATIVE AND ITS USE IN THE CHEMOTHERAPY OF PARASITIC INFECTIONS | GLAXO GROUP LIMITED (GB) | 2010-08-26 | — | — | WO | claimed |
| US-7629365-B2 | antimalarial agent; 3-chloro-6-(hydroxymethyl)-2-methyl-5-[4-({4-[(trifluoromethyl)oxy]phenyl}oxy)phenyl]-4(1H )-pyridinone | GLAXO GROUP LIMITED (GB) | 2009-12-08 | — | — | US | claimed |
| EP-2024332-A1 | NOVEL HETEROCYCLIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-02-18 | — | — | EP | claimed |
| US-20080021073-A1 | NOVEL HETEROCYCLIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-01-24 | — | — | US | claimed |
| WO-2007138048-A1 | NOVEL HETEROCYCLIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-06 | — | — | WO | claimed |
| US-20070281977-A1 | NOVEL HETEROCYCLIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-06 | — | — | US | claimed |
| CN-110545815-B | Medical application of cytochrome bc1 complex inhibitor | 北京蔚蓝之源医药科技有限公司 | 2024-07-05 | — | — | CN | disclosed |
| US-20230181564-A1 | Potent Tetrahydroquinolone Eliminates Apicomplexan Parasites | THE UNIVERSITY OF SHEFFIELD (GB) | 2023-06-15 | — | — | US | disclosed |
| CN-101932561-A | Crystalline forms of an antimalarial compound | GLAXO GROUP LTD | 2010-12-29 | — | — | CN | disclosed |
| WO-2010142741-A1 | PHENYLPYRIDYLPYRIDONES FOR USE AS ANTIMALARIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2010-12-16 | — | — | WO | disclosed |
| US-20100256199-A1 | Crystalline form of an Antimalarial Compound | GLAXO GROUP LIMITED | 2010-10-07 | — | — | US | disclosed |
| US-20100256199-A1 | Crystalline form of an Antimalarial Compound | GLAXO GROUP LIMITED | 2010-10-07 | — | — | US | disclosed |
| US-20100256199-A1 | Crystalline form of an Antimalarial Compound | GLAXO GROUP LIMITED | 2010-10-07 | — | — | US | disclosed |
| US-20080021073-A1 | NOVEL HETEROCYCLIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-01-24 | — | — | US | disclosed |
| WO-2007138048-A1 | NOVEL HETEROCYCLIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-06 | — | — | WO | disclosed |
| US-20070281977-A1 | NOVEL HETEROCYCLIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-06 | — | — | US | disclosed |
| US-20070281977-A1 | NOVEL HETEROCYCLIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-06 | — | — | US | disclosed |
| US-20070281977-A1 | NOVEL HETEROCYCLIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-06 | — | — | US | disclosed |
| US-20070281977-A1 | NOVEL HETEROCYCLIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-06 | — | — | US | disclosed |
| EP-1862459-A1 | Novel heterocyclic compounds | GLAXO GROUP LIMITED (GB) | 2007-12-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021073-A1 | NOVEL HETEROCYCLIC COMPOUNDS | CYP4B1, CYP3A4, G6PD | SLC2A1 4190/4885MMP2 3931/4885MMP9 4597/4885 |
| US-20230181564-A1 | Potent Tetrahydroquinolone Eliminates Apicomplexan Parasites | CYP11B2, CYP11B1, COX5B | SLC2A1 4289/4885MMP2 2948/4885MMP9 3019/4885 |
| US-20100256199-A1 | Crystalline form of an Antimalarial Compound | CYP3A43, G6PD, PYGL | SLC2A1 2074/4885MMP2 2438/4885MMP9 3817/4885 |
| US-20070281977-A1 | NOVEL HETEROCYCLIC COMPOUNDS | CYP4B1, CYP2C19, CYP3A4 | SLC2A1 4383/4885MMP2 3636/4885MMP9 3037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.